Skip to Late-Breaking Abstracts »

All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Poster Presentation Dates

All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.

Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.


Search word or phrase:

# Type Title Authors Category Keywords
161 Poster Presentation Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy Kathrin Davari, PHD; Tristan Holland; Laura Prassmayer; Giulia Longinotti; Kenneth Ganley; Lisa J. Pechilis; Iulia Diaconu; Prashant R. Nambiar; Mike S. Magee; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Christian Ellinger, Dr. Rer. Nat.; Cellular Therapies Adoptive immunotherapy; Solid tumors; T cell; Targeted therapy; Tumor antigens
271 Poster Presentation Consistent high-quality dendritic cell vaccines produced post-chemotherapy in patients with acute myeloid leukemia for use in a Phase I/II trial Frauke Schnorfeil; Christiane Geiger, PhD; Iris Bigalke; Dag Josefsen; Yngvar Floisand; Gunnar Kvalheim, MD, PhD; Dolores J. Schendel, PhD; Anna Tafuri; Kai Pinkernell; Completed Clinical Trials Antigen presenting cells; Dendritic cell; Leukemia/Lymphoma; Targeted therapy; Tumor antigens; Vaccine
614 Poster Presentation Co-stimulation via PD1-41BB chimeric switch receptor enhances function of TCR-T cells in an immune-suppressive milieu and under chronic antigen stimulation Melanie Salvermoser; Maria Gerget; Franziska Hasselmann; Elfriede Noessner, Prof. Dr.; Christian Ellinger, Dr. Rer. Nat.; Monika Braun; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Nadja Sailer, Dr. rer. nat.; Immuno-conjugates and chimeric molecules Adoptive immunotherapy; Checkpoint blockade; Costimulation; Solid tumors; T cell; Tumor microenvironment